share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股sec公告 ·  05/09 16:38
Moomoo AI 已提取核心信息
On May 9, 2024, eFFECTOR Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $50.0 million of its common stock. The sales may occur on the Nasdaq Capital Market, with the agent receiving a 3.0% commission on gross proceeds. The agreement includes indemnification provisions for the agent and can be terminated by either party with prior written notice. Concurrently, eFFECTOR Therapeutics terminated its previous agreement with Cantor Fitzgerald & Co., under which it had sold over 1 million shares for $9.8 million. The new sales agreement is part of a prospectus supplement to the company's effective registration statement filed with the SEC.
On May 9, 2024, eFFECTOR Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $50.0 million of its common stock. The sales may occur on the Nasdaq Capital Market, with the agent receiving a 3.0% commission on gross proceeds. The agreement includes indemnification provisions for the agent and can be terminated by either party with prior written notice. Concurrently, eFFECTOR Therapeutics terminated its previous agreement with Cantor Fitzgerald & Co., under which it had sold over 1 million shares for $9.8 million. The new sales agreement is part of a prospectus supplement to the company's effective registration statement filed with the SEC.
2024年5月9日,Effector Therapeutics, Inc.宣布与H.C. Wainwright & Co., LLC签订市场发行协议,允许该公司出售高达5000万美元的普通股。销售可能在纳斯达克资本市场上进行,代理商将获得总收益的3.0%的佣金。该协议包括对代理人的赔偿条款,任何一方都可以在事先书面通知的情况下终止。同时,Effector Therapeutics终止了先前与Cantor Fitzgerald & Co. 的协议,根据该协议,该公司以980万美元的价格出售了超过100万股股票。新的销售协议是公司向美国证券交易委员会提交的有效注册声明的招股说明书补充文件的一部分。
2024年5月9日,Effector Therapeutics, Inc.宣布与H.C. Wainwright & Co., LLC签订市场发行协议,允许该公司出售高达5000万美元的普通股。销售可能在纳斯达克资本市场上进行,代理商将获得总收益的3.0%的佣金。该协议包括对代理人的赔偿条款,任何一方都可以在事先书面通知的情况下终止。同时,Effector Therapeutics终止了先前与Cantor Fitzgerald & Co. 的协议,根据该协议,该公司以980万美元的价格出售了超过100万股股票。新的销售协议是公司向美国证券交易委员会提交的有效注册声明的招股说明书补充文件的一部分。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息